Companies / CYP

CYNATA THERAPEUTICS LIMITED

ASX:CYPPharmaceuticals, Biotechnology & Life Sciences
243.5M shares on issueASX (delayed) · as of 28 July 2026$0.011price · delayed$2.9Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 36% in 24 months; 4 cash raises in 24 months

Cash runway0.1 quarters of funding
Share-count growth (24m)35.5%
Raise cadence (24m)4 cash raises
Options & rights overhang4.5% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

CYNATA THERAPEUTICS LIMITED's ordinary share count rose 35.5% between July 2024 and May 2026 to 243M shares. The company completed four capital raises in that period with disclosed proceeds totalling A$10.8M, most recently raising A$1.5M in April 2026. Options and rights could convert into 11M new shares, equal to 4.5% of the current share count, with the nearest expiry in September 2026 and 0% currently in the money. At the March 2026 quarter CYNATA reported A$216K in available cash, covering 0.1 quarters at its recent cash burn rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
4.5%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
0.1 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 243.5M per ASX (delayed) (28 July 2026).
194.0M212.1M230.3MDec 24Sept 25July 26Cash raise · 29 Apr 2026Cash raise · 22 Jan 2026Cash raise · 4 June 2025Cash raise · 3 Dec 2024

Cash runway

0.1 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$216k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
9 July 20263H · cancellationCYP : ORDINARY FULLY PAID243.5MAppendix 3H
7 May 20262A · quoted issueCYP : ORDINARY FULLY PAID243.5MAppendix 2A
6 Apr 20263H · cancellationCYP : ORDINARY FULLY PAID237.5MAppendix 3H
30 Nov 20253H · cancellationCYP : ORDINARY FULLY PAID237.5MAppendix 3H
12 Oct 20253H · cancellationCYP : ORDINARY FULLY PAID237.5MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 2 in the last 12 months

$1.5M
Capital raise
29 Apr 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

4.5%
Total overhang · of current shares
0.0%
In the money · at current price
11.0M
Potential new shares
Sept 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
29 Nov 2025Dr Geoffrey BrookeSell313k2.5M—3Y notice
29 Nov 2025Dr Darryl MaherSell117k220k—3Y notice
29 Nov 2025Dr Paul K WottonSell—300k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

9 July 2026Notification of cessation of securities - CYP
5 July 2026Final Director's Interest Notice
5 July 2026$PBoard, Management Changes, Expenditure Reductions, RDTI Loan
2 July 2026Ceasing to be a substantial holder
1 July 2026Change in substantial holding
29 June 2026Becoming a substantial holder
23 June 2026Ceasing to be a substantial holder
21 June 2026Investor Webinar
18 June 2026$PReinstatement to Official Quotation
18 June 2026$PCYP-004 Osteoarthritis Trial Results
17 June 2026$PCYP-001 GvHD Trial Primary Evaluation Results
15 June 2026$PSuspension from Quotation
11 June 2026$PTrading Halt
2 June 2026$PEU Positive Opinion on CYP-001 Paediatric Investigation Plan
28 May 2026WHO Selects Proposed INN for Cymerus MSCs
26 May 2026Expected Timing of Clinical Trial Results
7 May 2026Cleansing Notice
7 May 2026Application for quotation of securities - CYP
3 May 2026Proposed issue of securities - CYP
3 May 2026$PCynata Secures Commitments for $1.5m Placement

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.